+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Reduction of Reperfusion Injury by Recombinant Human Superoxide Dismutase Administered Intravenously Just prior to Reperfusion

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The reduction of reperfusion injury by intravenous administration of recombinant human superoxide dismutase (r-hSOD) was evaluated in a dog model. Two hours of left anterior coronary artery clamping were followed by 30 min of partial reperfusion and 30 min of full reperfusion. In the SOD group, r-hSOD (100,000 U/kg) was given intravenously 5 min before reperfusion. Measured left ventricular (LV) segments were classified thermographically by temperature drop into central ( > 2°C) and marginal ( < 2°C) areas. The regional LV functions were evaluated by percentages of both segmental (%SS) and active (%AS) shortening. In the central area, the %SS values after reperfusion were -9% in the control group and -3% in the SOD group (p < 0.05). The respective %AS values were 6 and 29% (p < 0.01). In the marginal area, both groups had %SS values of-3% and respective %AS values of 34 and 22% (all not significant) after reperfusion. In the central area, there was significantly better LV function recovery in the SOD group than in the control group.

          Related collections

          Author and article information

          S. Karger AG
          14 November 2008
          : 82
          : 5
          : 354-364
          aFirst Department of Surgery, Saitama Medical School, Saitama; bDepartment of Cardiovascular Surgery, Showa General Hospital, cDepartment of Cardiovascular Surgery, Jikei University School of Medicine, Tokyo, Japan
          175886 Cardiology 1993;82:354–364
          © 1993 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 11
          Coronary Care


          Comment on this article